Key result
In rheumatoid arthritis patients on anti-TNF therapy, avoiding arthroplasty was associated with significantly lower average DAS28-CRP (P<0.001) and glucocorticoid use (P<0.05) at final survey.
Why the study?
Factors leading to arthroplasty due to joint destruction progression in RA patients treated with anti-TNF biological agents were unclear.
What factors are associated with the need for arthroplasty in rheumatoid arthritis patients treated with anti-TNF biological agents?
Cohort (n=91)
What factors are associated with the need for arthroplasty in rheumatoid arthritis patients treated with anti-TNF biological agents?
p-value: p=< 0.001
Maintaining tight control over rheumatoid arthritis activity is important to inhibit the need for joint surgery in patients using anti-TNF biological agents.
Tight RA control may reduce arthroplasty need on anti-TNF; observational data leave causality and practice change open.
The purpose of this study is to identify the factors that require arthroplasty due to the progression of joint destruction, even when an anti-tumor necrosis factor (TNF) biological agent is used for rheumatoid arthritis (RA). Among 91 cases that used the anti-TNF biological agent for more than 1 year, two groups of 21 cases that resulted in arthroplasty (surgery group) and 70 cases that did not result in arthroplasty (non-surgery group) were compared and examined. When the anti-TNF biological agent was first administered, disease activity and internal use of glucocorticoid (PSL) were not different in these two groups. The average DAS28-CRP(4) (disease activity score including a 28-joint count/C-reactive protein) (p < 0.001) and the amount of internal use of PSL (p < 0.05) were significantly decreased in the non-surgery group compared with the surgery group at the final survey. To inhibit the need for joint surgery in patients using the anti-TNF biological agent, it is important to maintain tight control over RA activity.
No takes yet. Share an insight, caveat, or question.
Sano et al. (2009) conducted a cohort in Rheumatoid arthritis (n=91). Anti-TNF biological agent therapy was evaluated on Average DAS28-CRP(4) and internal use of glucocorticoid at final survey (p=< 0.001). In rheumatoid arthritis patients on anti-TNF therapy, avoiding arthroplasty was associated with significantly lower average DAS28-CRP (P<0.001) and glucocorticoid use (P<0.05) at final survey.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: